Found: 59
Select item for more details and to access through your institution.
Clinical Outcomes of Patients With Breast Cancer in a Phase I Clinic: The M. D. Anderson Cancer Center Experience.
- Published in:
- Clinical Breast Cancer, 2010, v. 10, n. 1, p. 46, doi. 10.3816/CBC.2010.n.006
- By:
- Publication type:
- Article
Clinical trial design in the era of precision medicine.
- Published in:
- Genome Medicine, 2022, v. 14, n. 1, p. 1, doi. 10.1186/s13073-022-01102-1
- By:
- Publication type:
- Article
Inhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignancies.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Supportive care for the prevention of nausea, vomiting and anorexia in a phase 1B study of selinexor in advanced cancer patients: an exploratory study.
- Published in:
- Investigational New Drugs, 2022, v. 40, n. 1, p. 124, doi. 10.1007/s10637-021-01184-5
- By:
- Publication type:
- Article
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancer.
- Published in:
- Investigational New Drugs, 2018, v. 36, n. 3, p. 416, doi. 10.1007/s10637-017-0513-5
- By:
- Publication type:
- Article
Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies.
- Published in:
- Scientific Reports, 2016, p. 35448, doi. 10.1038/srep35448
- By:
- Publication type:
- Article
Dual EGFR blockade with cetuximab and erlotinib combined with anti-VEGF antibody bevacizumab in advanced solid tumors: a phase 1 dose escalation triplet combination trial.
- Published in:
- Experimental Hematology & Oncology, 2020, v. 9, n. 1, p. 1, doi. 10.1186/s40164-020-00159-1
- By:
- Publication type:
- Article
<i>FBXW7</i> Mutations in Patients with Advanced Cancers: Clinical and Molecular Characteristics and Outcomes with mTOR Inhibitors.
- Published in:
- PLoS ONE, 2014, v. 9, n. 2, p. 1, doi. 10.1371/journal.pone.0089388
- By:
- Publication type:
- Article
PIK3CA Mutations Frequently Coexist with RAS and BRAF Mutations in Patients with Advanced Cancers.
- Published in:
- PLoS ONE, 2011, v. 6, n. 7, p. 1, doi. 10.1371/journal.pone.0022769
- By:
- Publication type:
- Article
A nonparametric Bayesian basket trial design.
- Published in:
- Biometrical Journal, 2019, v. 61, n. 5, p. 1160, doi. 10.1002/bimj.201700162
- By:
- Publication type:
- Article
Physiologically‐based pharmacokinetic modelling to predict oprozomib CYP3A drug–drug interaction potential in patients with advanced malignancies.
- Published in:
- British Journal of Clinical Pharmacology, 2019, v. 85, n. 3, p. 530, doi. 10.1111/bcp.13817
- By:
- Publication type:
- Article
Precision Oncology: Evolving Clinical Trials across Tumor Types.
- Published in:
- Cancers, 2023, v. 15, n. 7, p. 1967, doi. 10.3390/cancers15071967
- By:
- Publication type:
- Article
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience.
- Published in:
- Cancer Medicine, 2016, v. 5, n. 12, p. 3437, doi. 10.1002/cam4.956
- By:
- Publication type:
- Article
Phase I-II Clinical Trial of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab Therapy in Aggressive Relapsed/Refractory Chronic Lymphocytic Leukemia or Richter Syndrome.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2013, v. 13, n. 5, p. 568, doi. 10.1016/j.clml.2013.03.012
- By:
- Publication type:
- Article
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Outcomes in patients with splenic marginal zone lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or chemotherapy alone.
- Published in:
- Cancer (0008543X), 2006, v. 107, n. 1, p. 125
- By:
- Publication type:
- Article
Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
- Published in:
- Cancer (0008543X), 2004, v. 100, n. 12, p. 2583
- By:
- Publication type:
- Article
Fractionated cyclophosphamide, vincristine, liposomal daunorubicin, and dexamethasone plus rituximab and granulocyte-macrophagecolony stimulating factor (GM-CSF) alternating with methotrexate and cytarabine plus rituximab and GM-CSF in patients with Richter syndrome or fludarabine-refractory chronic lymphocytic leukemia
- Published in:
- Cancer (0008543X), 2003, v. 97, n. 7, p. 1711, doi. 10.1002/cncr.11238
- By:
- Publication type:
- Article
Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD anderson cancer center experience.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Phase I clinical trial of lenalidomide in combination with bevacizumab in patients with advanced cancer.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2013, v. 72, n. 6, p. 1265, doi. 10.1007/s00280-013-2302-y
- By:
- Publication type:
- Article
Phase I clinical trial of hepatic arterial infusion of cisplatin in combination with intravenous liposomal doxorubicin in patients with advanced cancer and dominant liver involvement.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2010, v. 66, n. 6, p. 1087, doi. 10.1007/s00280-010-1266-4
- By:
- Publication type:
- Article
Mylotarg, fludarabine, cytarabine (ara-C), and cyclosporine (MFAC) regimen as post-remission therapy in acute myelogenous leukemia.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Anagrelide and imatinib mesylate combination therapy in patients with chronic myeloproliferative disorders.
- Published in:
- 2003
- By:
- Publication type:
- journal article
Mylotarg combined with topotecan and cytarabine in patients with refractory acute myelogenous leukemia.
- Published in:
- 2002
- By:
- Publication type:
- journal article
Outcomes of patients ≥65 years old with advanced cancer treated on phase I trials at MD ANDERSON CANCER CENTER.
- Published in:
- International Journal of Cancer, 2017, v. 140, n. 1, p. 208, doi. 10.1002/ijc.30417
- By:
- Publication type:
- Article
Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.
- Published in:
- Journal of Hematology & Oncology, 2023, v. 16, n. 1, p. 1, doi. 10.1186/s13045-023-01504-7
- By:
- Publication type:
- Article
Relevance of clinical trials in acute myeloid leukaemia.
- Published in:
- Hematological Oncology, 2008, v. 26, n. 3, p. 182, doi. 10.1002/hon.851
- By:
- Publication type:
- Article
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00369-w
- By:
- Publication type:
- Article
Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for early-phase oncology clinical trials.
- Published in:
- 2016
- By:
- Publication type:
- journal article
Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors.
- Published in:
- Cancer (0008543X), 2014, v. 120, n. 14, p. 2164, doi. 10.1002/cncr.28701
- By:
- Publication type:
- Article
Validation of the royal marsden hospital prognostic score in patients treated in the phase I clinical trials program at the MD Anderson Cancer Center.
- Published in:
- Cancer (0008543X), 2012, v. 118, n. 5, p. 1422, doi. 10.1002/cncr.26413
- By:
- Publication type:
- Article
A Phase 1 Study of Hepatic Arterial Infusion of Oxaliplatin in Combination With Systemic 5-Fluorouracil, Leucovorin, and Bevacizumab in Patients With Advanced Solid Tumors Metastatic to the Liver.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 17, p. 4086, doi. 10.1002/cncr.25277
- By:
- Publication type:
- Article
Epstein-Barr Virus Latent Membrane Protein 1 mRNA Is Expressed in a Significant Proportion of Patients With Chronic Lymphocytic Leukemia.
- Published in:
- Cancer (0008543X), 2010, v. 116, n. 4, p. 880, doi. 10.1002/cncr.24839
- By:
- Publication type:
- Article
Survival of patients in a Phase 1 Clinic: the M. D. Anderson Cancer Center experience.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Survival of Patients in a Phase 1 Clinic.
- Published in:
- Cancer (0008543X), 2009, v. 115, n. 5, p. 1091, doi. 10.1002/cncr.24018
- By:
- Publication type:
- Article
Post-Discharge Survival Outcomes of Patients with Advanced Cancer from the University of Texas MD Anderson Cancer Center Investigational Cancer Therapeutics (Phase I Trials) Inpatient Unit.
- Published in:
- Oncology, 2017, v. 92, n. 1, p. 14, doi. 10.1159/000449505
- By:
- Publication type:
- Article
First-In-Human Phase I Study of Tinengotinib (TT-00420), a Multiple Kinase Inhibitor, as a Single Agent in Patients With Advanced Solid Tumors.
- Published in:
- Oncologist, 2024, v. 29, n. 4, p. e514, doi. 10.1093/oncolo/oyad338
- By:
- Publication type:
- Article
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. 1100, doi. 10.1093/oncolo/oyad158
- By:
- Publication type:
- Article
Patient‐Reported Out‐of‐Pocket Costs and Financial Toxicity During Early‐Phase Oncology Clinical Trials.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 588, doi. 10.1002/onco.13767
- By:
- Publication type:
- Article
Overview of Ocular Side Effects of Selinexor.
- Published in:
- Oncologist, 2021, v. 26, n. 7, p. 619, doi. 10.1002/onco.13756
- By:
- Publication type:
- Article
Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience.
- Published in:
- Oncologist, 2011, v. 16, n. 9, p. 1292, doi. 10.1634/theoncologist.2011-0043
- By:
- Publication type:
- Article
Cardiovascular Toxicity Profiles of Vascular-Disrupting Agents.
- Published in:
- Oncologist, 2011, v. 16, n. 8, p. 1120, doi. 10.1634/theoncologist.2010-0432
- By:
- Publication type:
- Article
Outcomes of Patients with Advanced Non-Small Cell Lung Cancer Treated in a Phase I Clinic.
- Published in:
- Oncologist, 2011, v. 16, n. 3, p. 327, doi. 10.1634/theoncologist.2010-0308
- By:
- Publication type:
- Article
Case report: Fatal overwhelming post-splenectomy infection in a patient with metastatic angiosarcoma treated with immunotherapy.
- Published in:
- Frontiers in Immunology, 2024, p. 01, doi. 10.3389/fimmu.2024.1366271
- By:
- Publication type:
- Article
A pilot study of temsirolimus and body composition.
- Published in:
- Journal of Cachexia, Sarcopenia & Muscle, 2013, v. 4, n. 4, p. 259, doi. 10.1007/s13539-013-0113-y
- By:
- Publication type:
- Article
Phase 1/2 trial of avelumab combined with utomilumab (4‐1BB agonist), PF‐04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
- Published in:
- Cancer (0008543X), 2024, v. 130, n. 3, p. 400, doi. 10.1002/cncr.35063
- By:
- Publication type:
- Article
Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple‐negative breast cancer.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 14, p. 2201, doi. 10.1002/cncr.34773
- By:
- Publication type:
- Article